Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.27 -0.24 (-0.45%)

Delayed Quote Updated: 10:52 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market? ↗

September 30, 2026

Roche is increasingly looking like a notable contender in this fast-growing area.

Via The Motley Fool

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Via The Motley Fool

Topics Intellectual Property

BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried? ↗

September 18, 2026

BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.

Via The Motley Fool

Revolution Medicines Got Its Breakthrough—What Moves It Next? ↗

September 04, 2026

FDA approved Revolution Medicines' RASONQUE for pancreatic cancer, but RVMD stock stayed flat as investors had priced in the news early, with rising expenses now in focus.

Via MarketBeat

Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗

September 03, 2026

This biotech stock looks like a great candidate to buy on the admittedly steep dip.

Via The Motley Fool

2 Stocks That Could Capitalize on the GLP-1 Boom ↗

August 25, 2026

They aren't the most prominent names in the GLP-1 space, but they are worth a second look.

Via The Motley Fool

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

They are fairly risky, but their potential upside is massive.

Via The Motley Fool

Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗

August 14, 2026

Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

VYMI vs. VIGI: Which International Dividend ETF Is Better? ↗

July 09, 2026

When buying international dividend stocks, diversification is likely the best bet.

Via The Motley Fool

Topics Artificial Intelligence ETFs

The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗

July 08, 2026

As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities.

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗

July 02, 2026

These international stock ETFs from iShares and Vanguard are very different once you look under the surface.

Via The Motley Fool

Topics ETFs

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗

July 02, 2026

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Via The Motley Fool

Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗

June 29, 2026

These stocks are better bets to skyrocket than the much-hyped rocket stock.

Via The Motley Fool

Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks ↗

June 23, 2026

The long-term thesis remains largely unchanged.

Via The Motley Fool

Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗

June 19, 2026

Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum.

Via The Motley Fool

IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗

June 10, 2026

When buying international ETFs, owning more stocks in more countries might be a better bet.

Via The Motley Fool

Topics ETFs

President Trump's Drug Pricing Policies Could Hurt Drugmakers' Profits. Time to Sell Pharma Stocks? ↗

May 26, 2026

Don't be too quick to give up on the industry.

Via The Motley Fool

Topics Economy Government

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

The stock looks cheap, but appearances can be deceiving.

Via The Motley Fool

Topics Artificial Intelligence

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

Via The Motley Fool

Topics Artificial Intelligence ETFs

Eli Lilly Stock: Next Stop $2,000? ↗

May 18, 2026

The company is riding an incredible tailwind.

Via The Motley Fool

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Via The Motley Fool

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Via Finterra

Topics Earnings Economy Intellectual Property

Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Move into Immunology

April 06, 2026

In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis...

Via MarketMinute

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets

April 03, 2026

As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...

Via MarketMinute

Topics Intellectual Property

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

April 03, 2026

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Via MarketMinute

Topics Economy Government Lawsuit

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

Via MarketMinute

Topics Intellectual Property

The Trillion-Dollar Treatment: A Deep Dive into Eli Lilly and Company (LLY)

April 02, 2026

As of April 2, 2026, Eli Lilly and Company (NYSE:LLY) stands as the preeminent titan of the global healthcare sector. Historically recognized as a steady, century-old pharmaceutical giant, the company...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.